ArticleScience translational medicine2024
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.
Open access · goldAbstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Discovery of bioactive compounds from Thai medicinal plants as potential SARS-CoV-2 main protease inhibitors.RSC advances · 2026Article
- Substrate-Selective Inhibition of the SARS-CoV-2 Papain-Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Structure-based macrocyclization of α-ketoamides leads to potent inhibitors of coronaviral and enteroviral proteases.Communications chemistry · 2026Article
- Super-resolution atlas of SARS-CoV-2 infection reveals protease-dependent organelle maturation, dsRNA landscapes, and intracellular structural proteins.Nature communications · 2026Article
- Bioassay-Guided Phytochemical Investigation of VietnameseMolecules (Basel, Switzerland) · 2026Article
- Fast analysis and engineering of protein function by microbe-independent deep assembly and screening.Molecular systems biology · 2026Article
- Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitors.RSC chemical biology · 2026Review
- Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors.Current issues in molecular biology · 2026Article
- Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants.JACS Au · 2026Article
- Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.Journal of medicinal chemistry · 2026Article
- The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers.Computational and structural biotechnology journal · 2026Article
- Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor.Archiv der Pharmazie · 2025Article
- Article
- Structural insights into the nirmatrelvir-resistant SARS-CoV-2 MRSC medicinal chemistry · 2025Article
- Prospects for the structure‒function evolution of SARS-CoV-2 main protease inhibitors.Journal of computer-aided molecular design · 2025Review
- The role of SARS-CoV-2 main protease in innate immune regulation: From molecular mechanisms to therapeutic implications.Acta pharmaceutica Sinica. B · 2025Review
- Article
- Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor.bioRxiv : the preprint server for biology · 2025Article
- Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MScience advances · 2025Article
- Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease.Journal of medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 3 countries.
Michael WestbergDepartment of Neurobiology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-2312-5282
Yichi SuDepartment of Neurobiology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-5715-835X
Xinzhi ZouDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-3382-2401
Pinghan HuangDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-2460-0695
Arjun RustagiDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6921-1012
Jaishree GarhyanStanford In Vitro Biosafety Level 3 Service Center, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-1657-8320
Puja Bhavesh PatelStanford In Vitro Biosafety Level 3 Service Center, Stanford University, Stanford, CA 94305, USA.
Daniel FernandezProgram in Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6221-152X
Yan WuDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-2596-1943
Chenzhou HaoDepartment of Neurobiology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6803-7270
Chieh-Wen LoDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.
Marwah KarimDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-0990-3962
Lin NingDepartment of Neurobiology, Stanford University, Stanford, CA 94305, USA.
Aimee BeckDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.
Panatda Saenkham-HuntsingerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-9598-7255
Vivian TatDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0009-0002-0274-3900
Aleksandra DrelichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0002-0201-5017
Bi-Hung PengDepartment of Neuroscience, Cell Biology, and Anatomy, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-1323-2241
Shirit EinavDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6441-4171
Chien-Te K TsengDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-5726-9834
Catherine BlishDepartment of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6946-7627
Michael Z LinDepartment of Neurobiology, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-0492-1961
Stanford University · USThe University of Texas Medical Branch at Galveston · USChan Zuckerberg Initiative (United States) · USStanford Synchrotron Radiation Lightsource · USAarhus University · DKFudan University · CN
Funding
Translation Accelerator CoreU19AI171421 · NIAID · STANFORD UNIVERSITY · PI JEFFREY S GLENN · 2022 to 2026
$93.4MA Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3MEMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8MAdvancing the development of a novel class of small molecules for treating pan-coronavirus infectionsR01AI158569 · NIAID · STANFORD UNIVERSITY · PI EINAV, SHIRIT · 2021 to 2025
$3.7MNIAID NIH HHS R01 AI158569NIAID NIH HHS T32 AI007502NIAID NIH HHS U19 AI171421NIGMS NIH HHS P30 GM133894
Abstract
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M
Indexed as
Coronavirus 3C ProteasesCOVID-19Antiviral AgentsHumansMutationProtease InhibitorsSARS-CoV-23C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.